ArticleStem cell research & therapy2026
Animal-origin-free medium enhances G2/M progression while maintaining identity and genomic stability in human adipose-derived MSCs.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundMesenchymal stem cells (MSCs) are considered promising candidates for regenerative and immunomodulatory therapies. However, their clinical use requires xeno-free, good manufacturing practice (GMP)-compatible culture systems. Conventional serum-containing media (FCM) present variability and xenogeneic risk; as such, serum-free (SFM) and animal‑origin‑free (AOF) media have been produced to enhance reproducibility and safety. However, comparative analyses of MSC phenotype, function, and transcriptomic integrity across these media are scarce. Herein, we compared the features of MSC cultures in these different media.
methodsHuman adipose-derived MSCs from three donors were expanded in FCM, FDA-approved SFM, and AOF media at early, mid, and late passages. The growth kinetics, morphology, immunophenotype, and trilineage potential of these MSCs were assessed. Transcriptomic profiling (RNA-seq), pathway analysis, cell cycle inference, qRT-PCR confirmation, and copy number variation (CNV) analyses were further performed.
resultsAOF-supported MSCs exhibited the shortest population doubling time and stable morphology. AOF upregulated G2/M-phase regulators, including Cyclin B-CDK1 complexes and the anaphase-promoting complex/cyclosome, while downregulating negative proliferation and differentiation pathways. Cell cycle profiling confirmed G2/M enrichment. MSC identity (ISCT markers) and low inflammatory profiles, including reduced NGF and CSF1 levels, were maintained. CNV analysis showed no significant differences in genomic instability across media.
conclusionsAOF medium promoted MSC proliferation through selective G2/M activation while maintaining MSC identity, immunomodulation-related marker profiles, and genomic stability under the tested conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.